RxDoctor Payments Data

Daniel Enayati, MD

General Practice · South Gate, CANPI 1861525016

Payments from drug & device makers

$885in general payments, 2019–2025

Across 43 payments — averaging $20.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$319
  • Lilly USA, LLC$202
  • Johnson & Johnson$89
  • Boehringer Ingelheim$72
  • Novo Nordisk$67
  • Bayer$50
  • plus $85 from 3 others

What the payments were for

  • Food & beverage$87399%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$885 in reported general payments places this provider in the 75th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$54,463
Medicare patients
81
Services billed
1,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol113$85,755
JanuviaSitagliptin Phosphate101$78,160
JardianceEmpagliflozin78$76,527
OzempicSemaglutide47$47,694
JanumetSitagliptin Phos/Metformin Hcl40$28,527
KerendiaFinerenone32$22,742
SynjardyEmpagliflozin/Metformin Hcl31$18,303
VascepaIcosapent Ethyl42$15,325
TradjentaLinagliptin16$13,106
TrulicityDulaglutide12$12,809
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog44$12,509
Janumet XrSitagliptin Phos/Metformin Hcl17$10,824
Icosapent Ethyl33$10,176
Ibandronate Sodium242$7,380
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,063

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet, Janumet Xr$49$117,511158 claims
Boehringer IngelheimJardiance, Synjardy, Tradjenta$72$107,935125 claims
AstraZenecaFarxiga$319$85,755113 claims
Novo NordiskOzempic$67$47,69447 claims
BayerKerendia$50$22,74232 claims
Lilly USA, LLCTrulicity$202$12,80912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 12,963 general practice providers in California.

Other general practice in South Gate

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →